期刊
MUSCLE & NERVE
卷 59, 期 2, 页码 187-193出版社
WILEY
DOI: 10.1002/mus.26361
关键词
diabetic polyneuropathy; POCD; nerve conduction study; point-of-care nerve conduction device; sural nerve
资金
- International Diabetic Neuropathy Consortium (IDNC) research program - Novo Nordisk Foundation Challenge Programme [NNF14OC0011633]
- National Health Services
- Danish Council for Strategic Research
- Danish Research Foundation for General Practice
- Novo Nordisk Foundation
- Danish Center for Evaluation and Health Technology Assessment
- Danish National Board of Health
- Danish Medical Research Council
- Aarhus University Research Foundation
- Novo Nordisk Scandinavia AB
- Novo Nordisk UK
- ASTRA Denmark
- Pfizer Denmark
- GlaxoSmithKline Pharma Denmark
- Servier Denmark A/S
- HemoCue Denmark A/S
Introduction: Rapid and accessible methods for diagnosing diabetic polyneuropathy (DPN) have been developed, but not validated, in large cohorts of people with diabetes. Methods: The performance of a point-of-care device (POCD) was studied in 168 patients with type 2 diabetes, estimating the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) compared with conventional sural nerve conduction studies (NCS). Results: A POCD amplitude limit of 6 mu V increased the sensitivity (96%) and NPV (98%), but decreased the specificity (71%) and PPV (54%) compared with the 4-mu V limit, which had values of 78%, 92%, 89%, and 71%, respectively. POCD on both legs showed better performance than on 1 leg. POCD amplitudes and conduction velocities correlated significantly with conventional sural NCS, but POCD values were underestimated compared with NCS. Discussion: The POCD may be used as a suitable screening tool for detection of DPN. Patients with abnormal and borderline results should undergo conventional NCS. Muscle Nerve 59:187-193, 2019
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据